4ypg: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='4ypg' size='340' side='right' caption='[[4ypg]], [[Resolution|resolution]] 3.00Å' scene=''> | <StructureSection load='4ypg' size='340' side='right' caption='[[4ypg]], [[Resolution|resolution]] 3.00Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4ypg]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YPG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4YPG FirstGlance]. <br> | <table><tr><td colspan='2'>[[4ypg]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YPG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4YPG FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene></td></tr> | ||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">IFNA2, IFNA2A, IFNA2B, IFNA2C ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ypg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ypg OCA], [http://pdbe.org/4ypg PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4ypg RCSB], [http://www.ebi.ac.uk/pdbsum/4ypg PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4ypg ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ypg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ypg OCA], [http://pdbe.org/4ypg PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4ypg RCSB], [http://www.ebi.ac.uk/pdbsum/4ypg PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4ypg ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| Line 18: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 4ypg" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 4ypg" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Interferon|Interferon]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | |||
[[Category: Acqua, W F.Dall]] | [[Category: Acqua, W F.Dall]] | ||
[[Category: Oganesyan, V]] | [[Category: Oganesyan, V]] | ||
[[Category: Ifn-alpha2a]] | [[Category: Ifn-alpha2a]] | ||
[[Category: Immune system]] | |||
[[Category: Therapeutic mab]] | [[Category: Therapeutic mab]] | ||
Revision as of 12:39, 13 February 2019
Structural Insights Into the Neutralization Properties of a Human Anti-Interferon Monoclonal AntibodyStructural Insights Into the Neutralization Properties of a Human Anti-Interferon Monoclonal Antibody
Structural highlights
Function[IFNA2_HUMAN] Produced by macrophages, IFN-alpha have antiviral activities. Publication Abstract from PubMedWe report the three-dimensional structure of human interferon alpha-2A (IFN-alpha2A) bound to the Fab fragment of a therapeutic monoclonal antibody (sifalimumab; IgG1/k). The structure of the corresponding complex was solved at a resolution of 3.0 A using molecular replacement and constitutes the first reported structure of a human type I IFN bound to a therapeutic antibody. This study revealed the major contribution made by the first complementarity determining region (CDR) in each of sifalimumab light and heavy chains. These data also provided the molecular basis for sifalimumab mechanism of action. We propose that its interferon-neutralizing properties are the results of direct competition for IFN-alpha2A binding to the IFN receptor subunit 1 (IFNAR1) and do not involve inhibiting IFN-alpha2A binding to the IFN receptor subunit 2 (IFNAR2). Structural Insights Into the Neutralization Properties of the Fully Human, Anti-Interferon Monoclonal Antibody Sifalimumab.,Oganesyan V, Peng L, Woods RM, Wu H, Dall'Acqua WF J Biol Chem. 2015 Apr 29. pii: jbc.M115.652156. PMID:25925951[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||